FL | 59-2600232 | |
(State or other jurisdiction of | (IRS Employer | |
incorporation) | Identification No.) |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Under the terms of settlement: the AA Parties and the CPG Parties (collectively, the "Parties") the agreed to execute a new three (3) year lease for the Facility with renewable options. The new lease also confers upon American Antibiotics a three (3) year option to purchase the Facility, a 65,600 square foot manufacturing plant consisting of an approximately 40,000 s quare foot non-sterile area and an approximately 25,600 square foot sterile area for injectable Beta-Lactam antibiotics, and the approximately 4.4 acres on which the Facility is located.
Further, all prior agreements, financial obligations, understandings or other commitments between the Parties were terminated, superseded and extinguished with the execution of the Settlement Documents. The Press Release, the Settlement Agreement, the Facility Lease and the Note are attached as Exhibits 99.1 through 99.4, respectively.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Act or the Exchange Act, except as shall be expressly set fort h by specific reference in such filing.
GeoPharma, Inc. | ||||||||
Date: September 11, 2009 | By: | /s/ Mihir K. Taneja | ||||||
Mihir K. Taneja | ||||||||
Chief Executive Officer | ||||||||
GeoPharma, Inc. | ||||||||
Date: September 11, 2009 | By: | /s/ Carol Dore-Falcone | ||||||
Carol Dore-Falcone | ||||||||
Sr. VP/CFO (Chief Accounting Officer) | ||||||||
Exhibit No. | Description | |
EX-99.2 | ||
EX-99.1 | ||
EX-99.3 | ||
EX-99.4 |